{"filing":{"accession_number":"0001193125-26-331488","cik":"0000893949","ticker":"MD","company_name":"Pediatrix Medical Group, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"md-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/893949/000119312526331488/md-20260804.htm"},"events":[{"id":23858,"run_id":21579,"accession_number":"0001193125-26-331488","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Pediatrix Medical Group's quarterly financial results for the three and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the company \"issued a press release announcing the results of its operations\" and attaches the press release as Exhibit 99.1. The release reports net revenue of $488 million, net income of $40 million, diluted EPS of $0.49, and Adjusted EBITDA of $76 million for Q2 2026, along with six-month results and forward guidance for full-year 2026 Adjusted EBITDA of $280–$300 million. This is material to investors assessing the registrant's financial performance and operational trends.","company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24207,"accession_number":"0001193125-26-331488","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Pediatrix Medical Group's quarterly financial results for the three and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the company \"issued a press release announcing the results of its operations\" and attaches the press release as Exhibit 99.1. The release reports net revenue of $488 million, net income of $40 million, diluted EPS of $0.49, and Adjusted EBITDA of $76 million for Q2 2026, along with six-month results and forward guidance for full-year 2026 Adjusted EBITDA of $280–$300 million. This is material to investors assessing the registrant's financial performance and operational trends.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:22:53.954200+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24207,"accession_number":"0001193125-26-331488","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Pediatrix Medical Group's quarterly financial results for the three and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the company \"issued a press release announcing the results of its operations\" and attaches the press release as Exhibit 99.1. The release reports net revenue of $488 million, net income of $40 million, diluted EPS of $0.49, and Adjusted EBITDA of $76 million for Q2 2026, along with six-month results and forward guidance for full-year 2026 Adjusted EBITDA of $280–$300 million. This is material to investors assessing the registrant's financial performance and operational trends.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:22:53.954200+00:00","company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","filing_date":"2026-08-04"}]}